Terminal Access

Unlimited access to the most powerful analytical tools in finance.

Bloomberg Fair Value
20M Securities
50Y History
10Y Estimates
8.000+ News Daily
Subscribe for $2
Overview
Profile

Compugen stock

CGEN
IL0010852080
553001

Price

1.62
Today +/-
+0.03
Today %
+1.87 %

Compugen stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Compugen stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Compugen stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Compugen stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Compugen's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Compugen Stock Price History

DateCompugen Price
3/10/20251.62 undefined
3/9/20251.59 undefined
3/6/20251.66 undefined
3/5/20251.67 undefined
3/4/20251.68 undefined
3/3/20251.68 undefined
3/2/20251.81 undefined
2/27/20251.92 undefined
2/26/20251.85 undefined
2/25/20251.95 undefined
2/24/20251.94 undefined
2/23/20252.07 undefined
2/20/20252.10 undefined
2/19/20252.18 undefined
2/18/20252.23 undefined
2/17/20252.28 undefined
2/13/20252.22 undefined
2/12/20252.19 undefined
2/11/20252.19 undefined
2/10/20252.15 undefined

Compugen Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Compugen, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Compugen from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Compugen’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Compugen. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Compugen’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Compugen’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Compugen’s growth potential.

Compugen Revenue, EBIT and net profit per share

DateCompugen RevenueCompugen EBITCompugen Net Income
2030e86.21 M undefined0 undefined-8.58 M undefined
2029e50.32 M undefined-40.89 M undefined-37.2 M undefined
2028e48.53 M undefined-25.63 M undefined-32.43 M undefined
2027e47.7 M undefined-18.41 M undefined0 undefined
2026e39.7 M undefined-14.07 M undefined-10.81 M undefined
2025e34.26 M undefined-15.2 M undefined-11.45 M undefined
202427.86 M undefined-14.89 M undefined-14.23 M undefined
202333.46 M undefined-12.99 M undefined-18.75 M undefined
20227.5 M undefined-35.37 M undefined-33.69 M undefined
20216 M undefined-35.07 M undefined-34.2 M undefined
20202 M undefined-31.5 M undefined-29.7 M undefined
20190 undefined-28.88 M undefined-27.34 M undefined
201817.8 M undefined-23.23 M undefined-22.6 M undefined
20170 undefined-37.41 M undefined-37.07 M undefined
2016710,000 undefined-32.58 M undefined-31.51 M undefined
20159.28 M undefined-20.92 M undefined-20.16 M undefined
201412.37 M undefined-12.34 M undefined-11.09 M undefined
20133.55 M undefined-17.04 M undefined-14.08 M undefined
2012240,000 undefined-13.54 M undefined-13.63 M undefined
20110 undefined-11.98 M undefined-12 M undefined
20101.12 M undefined-7.88 M undefined-7.2 M undefined
2009250,000 undefined-7.63 M undefined-3.83 M undefined
2008340,000 undefined-12.91 M undefined-12.53 M undefined
2007180,000 undefined-12.46 M undefined-12.11 M undefined
2006220,000 undefined-13 M undefined-13.02 M undefined
2005650,000 undefined-13.73 M undefined-13.98 M undefined

Compugen Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
21437111162000001003129001702673327343947485086
--50.00300.00-25.00133.3357.14--45.45-66.67---------300.00-25.00-----200.0016.67371.43-18.1825.9314.7120.512.134.1772.00
50.00100.0075.0066.6771.4363.6472.7366.6750.00-----1,900.00--33.3375.0077.78--94.12-50.0083.3385.7193.9470.3755.8848.7240.4339.5838.0022.09
11325784100000000197001601563119000000
0-3-3-10-38-15-12-11-13-13-13-12-12-3-7-12-13-14-11-20-31-37-22-27-29-34-33-18-14-11-100-32-37-8
---233.33280.00-60.53-20.00-8.3318.18---7.69--75.00133.3371.438.337.69-21.4381.8255.0019.35-40.5422.737.4117.24-2.94-45.45-22.22-21.43-9.09--15.63-78.38
14.114.114.15.913.9126.0126.126.4127.4727.7727.9928.2728.4328.6133.2834.2835.8438.8747.8150.4450.8651.1855.2863.6479.5984.286.5687.6389.53000000
-----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Compugen Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Compugen is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                     
19.911.490.732.348.416.720.63125.415.111.515.621.822.424.851.373.880.860.529.445.143.2123.811783.350.69103.26
0.50.21.21.11.90.30.1000.707.8500007.80000200610
0.40.51.52.12.71.21.40.70.600.20.50.40.4000.20.60.10000.20.200.320.27
5004004001001000000000000000000000000
00000000.80.60.50.40.40.90.30.60.711.82.11.81.31.53.262.52.582.47
21.312.593.835.653.118.222.132.526.616.312.124.328.123.125.452759162.731.246.444.7129.2123.285.8114.58106
1.62.43.24.33.83.93.731.81.41.10.70.60.51.31.22.7664.63.45.64.53.93.42.553.7
00047.420.445.429.56.62.441.15.17.85.61.82.137.12.22.42.82.52.52.93.12.82.983.07
000000000000000000000000000
000000000000000000000000000
000000000000000000000000000
0.30.60.9000000000000.30.20.10.10.10.10.80.71.91.91.91.232.23
1.934.151.724.249.333.29.64.25.42.25.88.46.13.43.539.98.38.57.56.78.89.38.98.16.769
23.215.597.987.377.367.555.342.130.821.714.330.136.529.228.855.5114.999.371.238.753.153.5138.5132.193.9121.33115
                                                     
00100100100100100100100100100100100100100100100100100100200200200200200247248
26.231.4150.4150.4150152.3155.4155.9158.4161.2163.2184.5190.3195.7206.3235.4324.1328.8334.3337.4367.9396.3507.4528.5533.2539.84543.41
-6.8-14.9-53.2-68.4-80.6-92-105.8-119.7-132.8-144.9-157.5-161.3-168.5-180.5-194.1-208.2-219.3-239.5-271-308.2-330.8-358.2-387.9-422.1-455.8-474.53-488.76
-0.7-3.8-4.7-2-0.6-0.5-0.20014.24.16.44.35.44.61.20.4000000000.01
000000000000000000000000000
18.712.792.680.168.959.949.536.325.717.41027.428.319.617.731.9106.189.863.429.337.338.3119.7106.677.665.5654.91
1.91.63.14.94.83.63.13.52.82.82.91.42.31.41.22.44.46.54.86.12.91.11.44.61.83.51.84
0000000000000.20.30.1000005.758.48.89.811.628.69
1.20.51.211.61.60.30.20.40.20.10.10005.32.20.3001.30.80.73.60.311.159.63
1,00000000000000000000000000000
000000000000000000000000000
4.12.14.35.96.45.23.43.73.2331.52.51.71.37.76.66.84.86.19.96.910.51711.926.2720.16
000000000000000000000000000
000000000000000000000000000
0.40.61.11.422.52.42.221.51.21.35.77.89.917.12.32.62.93.35.98.688.44.629.5139.92
0.40.61.11.422.52.42.221.51.21.35.77.89.917.12.32.62.93.35.98.688.44.629.5139.92
4.52.75.47.38.47.75.85.95.24.54.22.88.29.511.224.88.99.47.79.415.815.518.525.416.555.7860.08
23.215.49887.477.367.655.342.230.921.914.230.236.529.128.956.711599.271.138.753.153.8138.213294.1121.33115
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Compugen provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Compugen's financial health and stability.

Assets

Compugen's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Compugen must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Compugen after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Compugen's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-3-3-8-13-15-12-11-13-13-13-12-12-3-7-12-13-14-11-20-31-37-22-27-29-34-33-18
0001,0001,0001,0001,0001,0001,0000000000001,0001,0001,0001,00000000
000000000000000000000000000
0200102-10000-10006-2-9725-3-26-5-20
002531111233046535655445886
00000000000000000000001,0001,0001,00000
000000000000000000000000000
-30-5-6-8-9-5-12-11-9-8-10-7-4-9-10-6-11-25-19-30-13-27-28-22-34-35
0-1-1-2-2-1-2-10000000-10-1-3-20000000
-1-1-1-12-635451573135-13-112-11-64101646-355-8263735
000-10-607771573135-13-113-11-62131846-355-8263735
000000000000000000000000000
000000200000000000000000000
91408700120000121028257202028251081603
91508700320000121099307202028251081603
000000000000007150000000000
000000000000000000000000000
514-869-72-32-34-1-4310-7-11012-3-14-115-203-2022
-3.7-1.84-7.56-8.17-11.72-10.52-7.94-13.64-11.97-9.62-8.46-10.18-7.5-4.33-9.35-11.86-6.77-13.05-28.73-22.42-31.05-13.45-28.05-28.49-23.04-35-36.06
000000000000000000000000000

Compugen stock margins

The Compugen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Compugen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Compugen.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Compugen's sales revenue. A higher gross margin percentage indicates that the Compugen retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Compugen's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Compugen's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Compugen's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Compugen. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Compugen's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Compugen Margin History

Compugen Gross marginCompugen Profit marginCompugen EBIT marginCompugen Profit margin
2030e71.54 %0 %-9.96 %
2029e71.54 %-81.26 %-73.92 %
2028e71.54 %-52.81 %-66.82 %
2027e71.54 %-38.59 %0 %
2026e71.54 %-35.45 %-27.23 %
2025e71.54 %-44.36 %-33.41 %
202471.54 %-53.44 %-51.07 %
202394.01 %-38.83 %-56.05 %
202287.07 %-471.6 %-449.2 %
202188.67 %-584.5 %-570 %
202097 %-1,575 %-1,485 %
201971.54 %0 %0 %
201894.21 %-130.51 %-126.97 %
201771.54 %0 %0 %
201669.01 %-4,588.73 %-4,438.03 %
201582.33 %-225.43 %-217.24 %
201472.92 %-99.76 %-89.65 %
201329.3 %-480 %-396.62 %
201216.67 %-5,641.67 %-5,679.17 %
201171.54 %0 %0 %
201079.46 %-703.57 %-642.86 %
2009100 %-3,052 %-1,532 %
200897.06 %-3,797.06 %-3,685.29 %
2007100 %-6,922.22 %-6,727.78 %
200695.45 %-5,909.09 %-5,918.18 %
200576.92 %-2,112.31 %-2,150.77 %

Compugen Stock Sales Revenue, EBIT, Earnings per Share

The Compugen earnings per share therefore indicates how much revenue Compugen has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Compugen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Compugen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Compugen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Compugen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Compugen Revenue, EBIT and net profit per share

DateCompugen Sales per ShareCompugen EBIT per shareCompugen Earnings per Share
2030e0.92 undefined0 undefined-0.09 undefined
2029e0.54 undefined0 undefined-0.4 undefined
2028e0.52 undefined0 undefined-0.35 undefined
2027e0.51 undefined0 undefined0 undefined
2026e0.42 undefined0 undefined-0.12 undefined
2025e0.37 undefined0 undefined-0.12 undefined
20240.31 undefined-0.17 undefined-0.16 undefined
20230.38 undefined-0.15 undefined-0.21 undefined
20220.09 undefined-0.41 undefined-0.39 undefined
20210.07 undefined-0.42 undefined-0.41 undefined
20200.03 undefined-0.4 undefined-0.37 undefined
20190 undefined-0.45 undefined-0.43 undefined
20180.32 undefined-0.42 undefined-0.41 undefined
20170 undefined-0.73 undefined-0.72 undefined
20160.01 undefined-0.64 undefined-0.62 undefined
20150.18 undefined-0.41 undefined-0.4 undefined
20140.26 undefined-0.26 undefined-0.23 undefined
20130.09 undefined-0.44 undefined-0.36 undefined
20120.01 undefined-0.38 undefined-0.38 undefined
20110 undefined-0.35 undefined-0.35 undefined
20100.03 undefined-0.24 undefined-0.22 undefined
20090.01 undefined-0.27 undefined-0.13 undefined
20080.01 undefined-0.45 undefined-0.44 undefined
20070.01 undefined-0.44 undefined-0.43 undefined
20060.01 undefined-0.46 undefined-0.47 undefined
20050.02 undefined-0.49 undefined-0.5 undefined

Compugen business model

Compugen Ltd is an Israeli biotechnology company focused on the development of therapeutics and diagnostic products. It was founded in 1993 and is headquartered in Tel Aviv. Compugen is one of the most popular companies on Eulerpool.com.

Compugen SWOT Analysis

Strengths

  • Established market presence and reputation in the IT industry.
  • Diverse range of products and services catered to various customer needs.
  • Strong research and development capabilities, enabling innovation and product improvement.
  • Strong financial position and stable revenue streams.
  • Well-trained and knowledgeable workforce, contributing to operational efficiency.
  • Solid partnerships with key industry players, enhancing market reach and competitiveness.

Weaknesses

  • Relatively small market share compared to industry giants.
  • Limited geographical presence, focusing primarily on specific regions.
  • Dependence on a few major clients for a significant portion of revenue.
  • Higher costs in research and development, impacting profitability.
  • Limited brand recognition and awareness compared to competitors.

Opportunities

  • Growing demand for IT solutions and services worldwide, offering potential for market expansion.
  • Emerging technologies, such as cloud computing and artificial intelligence, present new business avenues.
  • Strategic partnerships and joint ventures can help broaden customer base and enhance offerings.
  • Increasing emphasis on cybersecurity and data protection creates opportunities for specialized solutions.
  • Rising trend of remote work and digital transformation opens doors for IT infrastructure enhancement.

Threats

  • Intense competition from large, established IT companies.
  • Rapid technological advancements may render certain products or services obsolete.
  • Economic downturns and market instability can negatively impact customer spending on IT solutions.
  • Potential disruptions in the supply chain may lead to delays in delivery or increased costs.
  • Regulatory changes related to data privacy and cybersecurity can create compliance challenges.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Compugen Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Compugen historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Compugen shares outstanding

The number of shares was Compugen in 2024 — This indicates how many shares 89.528 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Compugen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Compugen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Compugen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Compugen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Compugen.

Compugen latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/20240.07 -0.07  (-193.58 %)2024 Q4
9/30/20240.11 0.01  (-90.69 %)2024 Q3
6/30/2024-0.07 -0.02  (71.59 %)2024 Q2
3/31/2024-0.02 -0.08  (-257.14 %)2024 Q1
12/31/20230.23 0.11  (-52.07 %)2023 Q4
9/30/2023-0.09 -0.11  (-16.77 %)2023 Q3
6/30/2023-0.13 -0.11  (14.26 %)2023 Q2
3/31/2023-0.12 -0.11  (9.39 %)2023 Q1
12/31/2022-0.15 -0.04  (72.49 %)2022 Q4
9/30/2022-0.13 -0.14  (-9.29 %)2022 Q3
1
2
3
4
5
...
6

Compugen shareholders

%
Name
Stocks
Change
Date
1.96785 % Bristol Myers Squibb1,840,136-2,916,92212/31/2024
1.73712 % SilverArc Capital Management, LLC1,624,377123,26412/31/2024
1.36584 % Renaissance Technologies LLC1,277,200-9,90012/31/2024
1.16891 % Taylor Frigon Capital Management LLC1,093,046-108,47712/31/2024
1.09079 % Macquarie Investment Management1,020,000012/31/2024
1.05870 % Rock Springs Capital Management LP989,990012/31/2024
1.00719 % Northern Trust Global Investments Limited941,825896,41112/31/2024
0.83268 % Morgan Stanley Smith Barney LLC778,63570,70612/31/2024
0.81973 % Antonetti Capital Management, LLC766,525-8,5529/30/2023
0.47824 % Dafna Capital Management, LLC447,202012/31/2024
1
2
3
4
5
...
10

Compugen Executives and Management Board

Dr. Anat Cohen-Dayag

(55)
Compugen President, Chief Executive Officer, Director (since 2002)
Compensation 1.3 M

Dr. Henry Adewoye

(57)
Compugen Senior Vice President, Chief Medical Officer
Compensation 836,868

Mr. Ari Krashin

(49)
Compugen Chief Financial Officer, Chief Operating Officer
Compensation 766,186

Dr. Oliver Froescheis

(56)
Compugen Senior Vice President, Corporate and Business Development
Compensation 666,349

Dr. Zurit Levine

(54)
Compugen Senior Vice President, Technology Innovation (since 2018)
Compensation 478,738
1
2
3

Most common questions regarding Compugen

What values and corporate philosophy does Compugen represent?

Compugen Ltd represents values of innovation, collaboration, and scientific excellence. As a leading biotechnology company, they strive to discover and develop novel therapeutic solutions to address unmet medical needs. Their corporate philosophy is centered around harnessing the power of artificial intelligence and deep learning algorithms to enable predictive identification and validation of drug targets. By leveraging their proprietary computational platforms, Compugen Ltd aims to revolutionize the field of immunology and oncology, ultimately improving patient outcomes. Through their commitment to pioneering research and strong partnerships, Compugen Ltd is dedicated to delivering innovative and effective treatments for complex diseases.

In which countries and regions is Compugen primarily present?

Compugen Ltd is primarily present in the United States, Israel, and Canada.

What significant milestones has the company Compugen achieved?

Compugen Ltd has achieved numerous significant milestones throughout its history. Some notable accomplishments include the discovery and validation of over 2,300 potential therapeutic targets, the development of innovative platforms for drug discovery, and the establishment of strategic partnerships with leading pharmaceutical companies. Additionally, Compugen Ltd has made advancements in the field of immuno-oncology, with the successful preclinical demonstrations of several novel immune checkpoint targets. These achievements showcase the company's commitment to pioneering research, collaboration, and progress in biotechnology. Compugen Ltd continues to strive towards revolutionizing the development of novel therapeutics for various diseases and solidifying its position as a key player in the industry.

What is the history and background of the company Compugen?

Compugen Ltd is a renowned biotechnology company based in Israel. Founded in 1993, the company specializes in predictive drug discovery and development using its proprietary computational technologies. With a focus on immuno-oncology, Compugen aims to harness the immune system's power to fight cancer effectively. Over the years, Compugen has established collaborations with leading pharmaceutical and biotech companies to accelerate its drug development programs. They have also generated a robust pipeline of novel, immune checkpoint targets for potential therapeutic interventions. With its innovative approach and strong expertise, Compugen Ltd strives to revolutionize cancer treatment and improve patient outcomes.

Who are the main competitors of Compugen in the market?

Compugen Ltd faces competition from various players in the market. Some of the main competitors of Compugen Ltd include industry giants like Gilead Sciences, Inc., Johnson & Johnson, and Bristol-Myers Squibb Company. These companies, along with others in the pharmaceutical and biotechnology sectors, pose a significant challenge to Compugen Ltd's market presence. However, Compugen Ltd's unique portfolio and innovative approach towards drug discovery and development help differentiate it from competitors and provide a competitive edge.

In which industries is Compugen primarily active?

Compugen Ltd is primarily active in the biotechnology industry.

What is the business model of Compugen?

The business model of Compugen Ltd is focused on drug and target discovery. Compugen utilizes its proprietary computational platforms and algorithms to identify novel targets for therapeutics and develop innovative drug candidates. By leveraging its expertise in predicting and validating target proteins, Compugen aims to accelerate the drug discovery and development process. Through collaborations with pharmaceutical companies and internal research and development efforts, Compugen seeks to bring novel therapeutics to the market to address unmet medical needs.

What is the P/E ratio of Compugen 2025?

The Compugen P/E ratio is -12.67.

What is the P/S ratio of Compugen 2025?

The Compugen P/S ratio is 4.23.

What is the Quality Investing of Compugen?

The Quality Investing for Compugen is 5/10.

What is the revenue of Compugen 2025?

The expected Compugen revenue is 34.26 M USD.

How high is the profit of Compugen 2025?

The expected Compugen profit is -11.45 M USD.

What is the business model of Compugen

Compugen Ltd. is a leading company in the development and marketing of computer-based solutions for biology and medicine. The company utilizes its extensive expertise in the field of bioinformatics to develop innovative software and data analysis tools that are applied in pharmacy, oncology therapies, and diagnostics. The business model of Compugen comprises several divisions. The first one involves the identification of target molecules that can be used for medical purposes. The company utilizes its ability to investigate complex biological data and extract relevant information from the analysis. The resulting insights are used to determine new targets for drug development. Another division of Compugen is drug development. The company focuses on the discovery of novel therapeutic targets and their implementation into successful and efficient medications. Compugen employs state-of-the-art technologies and methods such as immunomodulation and inhibition of tumor growth. Furthermore, the company also has its own diagnostic platform. This platform aims to assist doctors and patients in making more targeted diagnoses and selecting appropriate therapies. Compugen relies on its expertise in the analysis of biomarkers and diagnostic biomolecules. Another area of activity for the company is the development of software products. Compugen offers its customers software tools tailored to specific needs, which support the analysis of biological data and the development of new medications. Overall, the business model of Compugen is characterized by a high focus on innovation and research. The company aims to support its customers in the development of new diagnosis and treatment possibilities based on modern and data-driven bioinformatics. With its products and services, Compugen targets a wide range of applications. From pharmacy to precision medicine and diagnostics, the company offers diverse solutions to its customers. It can draw on a successful history of development partnerships and strategic alliances, which have provided it with important positions and a global presence. In summary, the business model of Compugen Ltd. is shaped by its expertise in bioinformatics, a high willingness to innovate, and close collaboration with customers and partners. Through its various divisions, it offers a broad range of products targeting different application areas and emphasizing high quality and scientific competence.

What is the Compugen dividend?

Compugen pays a dividend of 0 USD distributed over payouts per year.

How often does Compugen pay dividends?

The dividend cannot currently be calculated for Compugen or the company does not pay out a dividend.

What is the Compugen ISIN?

The ISIN of Compugen is IL0010852080.

What is the Compugen WKN?

The WKN of Compugen is 553001.

What is the Compugen ticker?

The ticker of Compugen is CGEN.

How much dividend does Compugen pay?

Over the past 12 months, Compugen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Compugen is expected to pay a dividend of 0 USD.

What is the dividend yield of Compugen?

The current dividend yield of Compugen is .

When does Compugen pay dividends?

Compugen pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Compugen?

Compugen paid dividends every year for the past 0 years.

What is the dividend of Compugen?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Compugen located?

Compugen is assigned to the 'Health' sector.

Wann musste ich die Aktien von Compugen kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Compugen from 3/12/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/12/2025.

When did Compugen pay the last dividend?

The last dividend was paid out on 3/12/2025.

What was the dividend of Compugen in the year 2024?

In the year 2024, Compugen distributed 0 USD as dividends.

In which currency does Compugen pay out the dividend?

The dividends of Compugen are distributed in USD.

All fundamentals about Compugen

Our stock analysis for Compugen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Compugen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.